TCR2 THERAPEUTICS INC (TCRR) Stock Price & Overview
NASDAQ:TCRR • US87808K1060
Current stock price
The current stock price of TCRR is 1.48 USD. Today TCRR is down by -5.73%. In the past month the price decreased by -17.32%. In the past year, price decreased by -38.59%.
TCRR Key Statistics
- Market Cap
- 58.107M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.20
- Dividend Yield
- N/A
TCRR Stock Performance
TCRR Stock Chart
TCRR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TCRR. When comparing the yearly performance of all stocks, TCRR is a bad performer in the overall market: 69.05% of all stocks are doing better.
TCRR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRR. TCRR has a bad profitability rating. Also its financial health evaluation is rather negative.
TCRR Earnings
TCRR Forecast & Estimates
12 analysts have analysed TCRR and the average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48.
TCRR Groups
Sector & Classification
TCRR Financial Highlights
Over the last trailing twelve months TCRR reported a non-GAAP Earnings per Share(EPS) of -4.2. The EPS decreased by -49.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TCRR Ownership
TCRR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 369.265B | ||
| AMGN | AMGEN INC | 15 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.84 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.51 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.71 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.55 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.4 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCRR
Company Profile
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Company Info
IPO: 2019-02-14
TCR2 THERAPEUTICS INC
100 Binney St
Cambridge MASSACHUSETTS 02142 US
CEO: Garry E. Menzel
Employees: 58
Phone: 16179495200.0
TCR2 THERAPEUTICS INC / TCRR FAQ
What does TCRR do?
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
What is the current price of TCRR stock?
The current stock price of TCRR is 1.48 USD. The price decreased by -5.73% in the last trading session.
What is the dividend status of TCR2 THERAPEUTICS INC?
TCRR does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCRR stock?
TCRR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists TCRR stock?
TCRR stock is listed on the Nasdaq exchange.
Is TCR2 THERAPEUTICS INC (TCRR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TCRR.
Can you provide the upcoming earnings date for TCR2 THERAPEUTICS INC?
TCR2 THERAPEUTICS INC (TCRR) will report earnings on 2023-08-07, before the market open.